A joint study was performed by MVIC member companies Emmace and Galenica together with MVIC customer Orion. Three different fixed dose combinations consisting of Indacaterol maleate and Glycopyrronium bromide were developed and tested in the Easyhaler® inhaler. The aim of the study was to modify the in vitro dispersibility profiles by altering the fine particle fraction using different mixing energies for the three different formulations. The performance of the three formulations in Easyhaler® was then compared with the performance of the reference inhaler Ultibro® Breezhaler® in an in vivo PK study. Read the full article.